GlassScriptPhysician profile
Vip Mangalick
NPI 1437347697
$7,020.46
in general payments reported to CMS, 2019-2025
36 companies · $1,526 in 2025
The $1,526 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,334 · 2020: $838 · 2021: $502 · 2022: $772 · 2023: $904 · 2024: $1,144 · 2025: $1,526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,561 · Education: $13.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,560.71 |
| Education | $13.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,169.11 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $1,141.35 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $796.82 | 2019-2025 | Farxiga, Breztri |
| Amgen INC. | $517.27 | 2021-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $395.40 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $381.30 | 2019-2020 | |
| Glaxosmithkline, LLC. | $371.06 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $325.66 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $282.27 | 2020-2025 | Spravato |
| Allergan, INC. | $238.61 | 2020 | |
| Abbott Laboratories | $194.02 | 2022-2025 | Proclaim, Octrode |
| Merck Sharp & Dohme LLC | $155.76 | 2019-2025 | Gardasil 9, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $137.13 | 2022-2025 | |
| Exact Sciences Corporation | $131.51 | 2023-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $117.93 | 2025 | Symbravo, Auvelity |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $105.80 | 2024-2025 | Korlym |
| Abbvie INC. | $70.35 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.92 | 2022-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $41.25 | 2023 | Rexulti |
| Dexcom, INC. | $40.33 | 2024-2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $36.16 | 2022-2023 | Quviviq |
| Acadia Pharmaceuticals INC | $32.48 | 2024 | Daybue |
| Genzyme Corporation | $32.02 | 2024 | |
| Medtronic, INC. | $31.38 | 2025 | Intellis Adaptivestim, Venaseal |
| Xeris Pharmaceuticals, INC. | $24.80 | 2023 | Keveyis |
| Array Biopharma INC | $20.88 | 2023 | Paxlovid, Comirnaty, Prevnar 20 |
| Lexicon Pharmaceuticals, INC. | $20.28 | 2024 | |
| Inspire Medical Systems, INC. | $19.93 | 2025 | Inspire |
| Ultragenyx Pharmaceutical INC. | $19.89 | 2022 | |
| Tris Pharma INC | $17.66 | 2022 | |
| Optinose US, INC. | $17.12 | 2022 | |
| Nevro Corp. | $15.94 | 2024 | Senza |
| Biogen, INC. | $15.65 | 2025 | |
| Exeltis, USA INC. | $14.51 | 2024 | Slynd |
| Antares Pharma, INC. | $14.21 | 2023 | Nocdurna, Xyosted, Tlando |
| Corium, LLC | $5.70 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vip Mangalick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.